Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Clinical cancer immunotherapy: Current progress and prospects
C Liu, M Yang, D Zhang, M Chen, D Zhu - Frontiers in immunology, 2022 - frontiersin.org
Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …
robust therapeutic potential in clinical practice. It can significantly improve progression-free …
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
Lighting up the fire in the microenvironment of cold tumors: A major challenge to improve cancer immunotherapy
Immunotherapy includes immune checkpoint inhibitors (ICI) such as antibodies targeting
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death …
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death …
Adaptive immune receptor repertoire analysis
B cell and T cell receptor repertoires compose the adaptive immune receptor repertoire
(AIRR) of an individual. The AIRR is a unique collection of antigen-specific receptors that …
(AIRR) of an individual. The AIRR is a unique collection of antigen-specific receptors that …
[HTML][HTML] Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
M Hiltensperger, AM Krackhardt - Frontiers in Immunology, 2023 - frontiersin.org
Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its
immune-oncology pipeline over the last years. This is in great part due to the recent …
immune-oncology pipeline over the last years. This is in great part due to the recent …
The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better
The overall efficacy of chimeric antigen receptor modified T cells (CARTs) remain limited in
solid tumors despite intensive studies that aim at targeting multiple antigens, enhancing …
solid tumors despite intensive studies that aim at targeting multiple antigens, enhancing …
Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches
V Geurts, M Kok - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement In approximately 15–20% of the patients diagnosed with breast cancer, it
comprises the triple negative (TN) subtype, which until recently lacked targets for specific …
comprises the triple negative (TN) subtype, which until recently lacked targets for specific …
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
J Li, Z Xiao, D Wang, L Jia, S Nie, X Zeng, W Hu - Molecular Cancer, 2023 - Springer
Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …
Amyloid-β specific regulatory T cells attenuate Alzheimer's disease pathobiology in APP/PS1 mice
Abstract Background Regulatory T cells (Tregs) maintain immune tolerance. While Treg-
mediated neuroprotective activities are now well-accepted, the lack of defined antigen …
mediated neuroprotective activities are now well-accepted, the lack of defined antigen …